Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2017

Planlagt Fastgjort Låst Flyttet Genmab
4.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • V Offline
    V Offline
    Vitus
    wrote on sidst redigeret af
    #122

    Vores sprogbrug er forskellig......heldigvis for det !

    1 Reply Last reply
    0
    • A Offline
      A Offline
      AaBforever
      wrote on sidst redigeret af
      #123

      Spændende når vi når 21. nov...

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #124

        Vil skal vel nok til at kalde det Cami-t - ikke at forveksle med camille-te 😉

        1 Reply Last reply
        0
        • A Offline
          A Offline
          AaBforever
          wrote on sidst redigeret af
          #125

          Accepteret late breaking med outstanding data på Alcyone er efter min mening den eneste kortsigtede kurstrigger.

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #126

            Tja, med mindre recepttallene pludselig begynder at sparke røv

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #127

              Hvis bare safety profilen for Cami-t er som camille te, så kald du det hvad du vil !!

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #128

                .. eller med mindre Winkel synger en sang fra de varme lande på næste onsdag.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #129

                  ligeledes spændende fra Karyopharm (selinexor):

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #130

                    The four STOMP presentations will include updated data from the arms evaluating selinexor in combination with Velcade® (bortezomib) and low-dose dexamethasone (SVd), selinexor in combination with Pomalyst® (pomalidomide) and low-dose dexamethasone (SPd), and selinexor in combination with Revlimid® (lenalidomide) and low-dose dexamethasone (SRd), and preliminary data from the arm evaluating selinexor in combination with Darzalex® (daratumumab) and low-dose dexamethasone (SDd).

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #131

                      Link Preview Image
                      Webprogram Unavailable

                      favicon

                      (ash.confex.com)

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #132

                        Conclusions – Selinexor 100 mg QW, can be combined safely with daratumumab and dex. The activity observed in the first 3 pts is promising with all 3 pts responding to therapy. Enrollment is ongoing and updated data from 100 mg QW cohort, 100 mg QW expansion, and full phase 1 will be updated and presented.

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #133

                          Poseida Therapuetics paper on CAR-T; apparantly they are collaborating with J&J’s Janss
                          en to develop this... didn't know that... https://ash.confex.com/ash/2017/webprogram/Paper108439.html

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #134

                            After 3 years of median follow-up, single-agent DARA continues to demonstrate a favorable safety profile with no new safety signals. Deep and durable responses continue to be maintained in a subset of these heavily pretreated patients. With over one-third of patients remaining alive after 3 years of study entry, these findings highlight the activity of single-agent DARA

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #135

                              Link Preview Image
                              Webprogram Unavailable

                              favicon

                              (ash.confex.com)

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #136

                                An accelerated infusion rate of daratumumab delivering 20% of the dose over 30 minutes and 80% over 60 minutes is feasible and well-tolerated in patients who have received 2 prior doses of daratumumab at standard infusion rates. Starting with the third dose of daratumumab therapy, the 90-minute infusion is now standard practice at our institution. https://ash.confex.com/ash/2017/webprogram/Paper102870.html

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #137

                                  Det er et par rigtig gode oplysning gentogen !

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #138

                                    tak gentogen. Lad os håbe det breder sig (og det gør det nok) indtil sc dara løser problemet endegyldigt.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #139

                                      90 minutes! hadn't heard about that yet; that will indeed solve a lot of practical problems for now!

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #140

                                        ASH overview from JNJ:
                                        https://www.jnj.com/media-center/press-releases/ash-2017-janssen-to-present-40-abstracts-including-8-oral-presentations-with-new-data-on-darzalex-daratumumab-imbruvica-ibrutinib-and-other-compounds-from-robust-portfolio?utm_source=Direct

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #141

                                          shows the most important for them is sc, smoldering, Castor & Pollux i guess

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger